Immune evasion by muscle-specific gene expression in dystrophic muscle

Molecular Therapy

Volumn 4, Issue 6, 2001, Pages 525-533

  Hartigan O'Connor, Dennis ^a   Kirk, Christopher J ^b   Crawford, Robert ^a   Mulé, James J ^b   Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adenovirus; Antigen presenting; Cross presentation; Cross priming; Dystrophin; Dystrophy; Gene therapy

Indexed keywords

BETA GALACTOSIDASE; VIRUS ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MOUSE; MUSCLE TISSUE; NONHUMAN; PROMOTER REGION; TISSUE SPECIFICITY; TRANSGENE;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA;

EID: 0035667634     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0496     Document Type: Article

References (50)

1. Developments in gene therapy for muscular dystrophy
2. Association of dystrophin and an integral membrane glycoprotein
3. Structure and mutation of the dystrophin gene
4. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase
5. The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice
6. X chromosome-linked muscular dystrophy (mdx) in the mouse
7. The mutant mdx: Inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates
8. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: Evidence of apoptosis in dystrophin-deficient muscle
9. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury
10. Force and power output of fast and slow skeletal muscles from young, adult, and old mdx mice
11. Electron microscopic and autoradiographic characterization of hind limb muscle regeneration in the mdx mouse
12. Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy
13. Apoptosis precedes necrosis of dystrophin-deficient muscle
14. Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders
15. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles
16. Cross-presentation, dendritic cells, tolerance and immunity
17. Processing of engulfed apoptotic bodies yields T cell epitopes
18. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction
19. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines
20. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors
21. Targeting adenovirus
22. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
23. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
24. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
25. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies
26. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy
27. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
28. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D
29. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells
30. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation
31. Neuromuscular transmission in the mdx mouse
32. Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants
33. Regulation of creatine kinase induction in differentiating mouse myoblasts
34. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine SCID mutation
35. b-restricted CTL epitope of β-galactosidase: Potential use in development of immunization protocols for "self" antigens
36. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells
37. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis
38. Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in different inflammatory myopathies
39. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity
40. Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle
41. Cutting edge: Recombinant adenoviruses induce CD8T cell responses to an inserted protein whose expression is limited to nonimmune cells
42. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors
43. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice
44. Immune responses to dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
45. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors
46. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
47. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy
48. Factors that influence stability of recombinant adenoviral preparations for human gene therapy
49. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
50. Use of E. coli lacZ (β-galactosidase) as a receptor gene